MétaCan
Menu
← Back to cohort

Peripheral Blood Stem Cell Harvests Performed Beyond the Initial Two Days of Apheresis May Not Contribute to Accelerate Granulocyte and Platelet Engraftment After Autologous Stem Cell Transplantation.

2009· article· en· W2555341938 on OpenAlexaff
Luciano Wannesson, Lisa Wang, John Kuruvilla, Tracy Nagy, R Saragosa, Norman Franke, Armand Keating, Michael Crump

Bibliographic record

VenueBlood · 2009
Typearticle
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsPrincess Margaret Cancer CentreUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsLeukapheresisMedicineApheresisCD34Stem cellEtoposideTransplantationHaematopoiesisCyclophosphamideGranulocyte colony-stimulating factorInternal medicineChemotherapyImmunologyUrologyPlateletBiology

Abstract

fetched live from OpenAlex

Abstract Abstract 3226 Poster Board III-163 Introduction Measurement of the number of CD34+ cells in the leukapheresis product is universally used as a surrogate measure of the capacity of peripheral blood stem cells (PBSC) to reconstitute hematopoiesis. Early studies demonstrated that engraftment times are shorter and predictable if at least 5 ×106 CD34+ cells/kg are administered following high-dose chemotherapy. However, satisfactory neutrophil and platelet recovery occurs after infusions of >2.0 ×106 CD34+ cells/kg. Previous analyses demonstrated the presence of different subsets of CD34+ cells in the peripheral blood at different times during mobilization, with pluripotent subsets arising and decreasing earlier after mobilization and more committed subsets peaking later [Stewart et al, Exp Hematol 1995; 23: 1619-27]. We hypothesized that for equivalent CD34+ cell dose, there could be a difference in engraftment kinetics according to the number of days of apheresis required to obtain an adequate PBSC graft. Patients and Methods Data from 270 consecutive autografts performed between July 1999 and April 2006 for non-Hodgkin and Hodgkin lymphoma (58% and 25%, respectively), breast cancer (8%), germ-cell tumors (2%) and acute myeloid leukemia (7%) were analyzed. Mobilization was performed using cyclophosphamide +/- etoposide + G-CSF 10μg/kg; patients received G-CSF after PBSC infusion from day 10 until neutrophil recovery >1500/μL. Patients were stratified in 3 groups according to the SC dose administered as follows: Low-dose (L) <2 ×106 CD34+ cells/kg, Intermediate-dose (I) 2 to 5 ×106 CD34+ cells/kg and High-dose (H) >5 ×106 CD34+ cells/kg and in 2 categories according to the number of days of apheresis performed (≤2 and 3+). The data analysis was divided in 3 steps. Step 1: we made a comparison of engraftment results for group L vs. I and I vs. H. Step 2: to explore potential engraftment differences within each cell dose stratum according to the number of days of apheresis required, that is, I(≤2) vs. I(3+) and H(≤2) vs. H(3+). Step 3: to test the influence of performing additional harvests beyond day 2 on engraftment kinetics we compared group I(≤2) vs. group H(3+), i.e. those who obtained the optimal number of CD34+ cells through additional collections during the same mobilization. Differences between groups were estimated by the Mann-Whitney test and by Cox regression model. Results The step 1 analysis confirmed that engraftment was faster for the H group (N=138, median 11 days for ANC>500/μl and N=132, median 11 days for unsupported platelet count >20000/μl) than for the I group (N=118, median 11 days and N=98, 12 days for neutrophils and platelets, respectively) and the L group (N=14, median 12 days and N=12, median 15 days for neutrophils and platelets, respectively). Two-sided p-values favored I in L vs. I (p=0.0185 for neutrophils and p=0.0013 for platelets) and favored H in I vs. H (p=0.0002 for neutrophils and p=0.019 for platelets). The step 2 analysis did not show any statistical difference in engraftment times within groups L, I and H, according to the number of apheresis (≤2 vs. 3+), but there was a trend for faster platelet engraftment for patients in the ≤2 group (p=0.08). There was no difference between the ≤2 and 3+ subgroups in terms of age and number of chemotherapy lines received before transplant; although, in the ≤2 group there were more patients with breast cancer (10.3% vs. 4.8%) and Hodgkin lymphoma (32.2% vs. 16.1%) and fewer pts with non-Hodgkin lymphoma (66.1% vs. 48%) compared to the 3+ group (p<0.001). Step 3 analysis showed no difference for neutrophil recovery between subgroups I≤2 and H3+ (N=28, median 11 days for I≤2 and N=20, median 10 days for H3+, p=0.08) and platelet engraftment (median 11 days for I≤2 and 12 days for H3+, p=0.54). Even dough, patients in the I≤2 cohort received significantly less CD34+ cells/kg (median 4.46, range 2.10-4.99) compared to those in the H3+ group (median 6.33, range 5.10-8.99, p<0.001) and were similar in terms of age and number of lines of prior therapy. Conclusions Provided more than 2 ×106 CD34+ cells/kg are obtained in two days of leukapheresis, optimal engraftment times can be achieved even if the threshold of 5 ×106 CD34+ cells/kg is not reached. Our results suggest that the addition of harvest days beyond 2 days to obtain ≥5 ×106 CD34+ cells/kg may not contribute to improved short-term engraftment kinetics. Disclosures No relevant conflicts of interest to declare.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.273
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2009
Admission routes1
Has abstractyes

Explore more

Same venueBlood→Same topicAcute Myeloid Leukemia Research→French-language works237,207→